Brain bleed drug dose may not be One-Size-Fits-All, study investigates
NCT ID NCT07065903
Summary
This study aims to understand why the standard dose of the drug nimodipine, given after a life-threatening brain bleed (aneurysmal subarachnoid hemorrhage), might not work the same for everyone. Researchers will measure drug levels in the blood of 500 adult patients in North America and see how they relate to recovery 90 days later. The goal is to gather information that could lead to more personalized dosing recommendations in the future.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUBARACHNOID HEMORRHAGE, ANEURYSMAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Health Network - Toronto Western Hospital
RECRUITINGToronto, Ontario, M5T 2S8, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Alberta Hospital
RECRUITINGEdmonton, Alberta, T6G 2X8, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
VCU Medical Center
RECRUITINGRichmond, Virginia, 23219, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.